Ensysce Biosciences receives $14M NIH grant for novel opioid development

Ensysce Biosciences announced receipt of a $14 million multi-year grant from the NIH and National Institute on Drug Abuse for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection that received Breakthrough Therapy designation from the FDA in January 2024. Funding from this award will be available over a period of approximately three years, allowing for the completion of the Phase 1b clinical trial, PF614-MPAR-102. This Phase 1b study is designed to expand the product offering identified in the PF614-MPAR-101 study, the first study to verify the overdose protection of the Multi-Pill Abuse Resistance platform. Combined, the two studies will help position PF614-MPAR as the first opioid product with oral overdose protection.